What it means
The central question in merger analysis is simple: does the buyer get more value than it gives up? Analysts value the target on its own, estimate the synergies the combination should produce, and then compare the total against the price and structure of the offer.
A standard analysis has several layers. Valuation work uses discounted cash flow, comparable company multiples and recent deal prices; the accretion and dilution test asks whether the combined earnings per share would be higher or lower than the buyer's own; and a sources and uses schedule shows exactly where the money comes from and where it goes.
Accretion and dilution is the piece most often quoted in board meetings because it is quick to calculate and easy to compare. A deal is accretive if the combined earnings per share exceed what the buyer would have reported alone, and dilutive if they fall, though a dilutive deal can still be worth doing if the strategic case is strong enough.
Sensible analysis pays as much attention to structure as to price. Paying in cash funded by debt raises interest cost and financial risk, paying in shares hands away part of the future upside, and most real deals blend the two to balance those effects.
The nuance that catches people out is that synergy estimates are assumptions, not facts. Good analysis splits them into cost synergies, which are relatively predictable, and revenue synergies, which are far softer, and then tests what happens if only half of them arrive.
In practice
Real-world examples.
Example
A private hospital group runs merger analysis on a chain of three clinics and finds the deal is 3% dilutive in year one but 7% accretive by year three once duplicated management roles are removed. The board approves it on the strength of the longer view, with the integration milestones written into the chief executive's bonus.
Example
A food manufacturer analysing a competitor discovers that two thirds of the projected synergies come from cross-selling rather than cost cutting. Because revenue synergies rarely arrive in full, the finance team rebuilds the model with those benefits halved and the offer price drops by $18,000,000 before it goes to the board.
Example
A logistics buyer compares funding the same $200,000,000 deal with debt or with shares. The debt version is more accretive to earnings per share but pushes the group's borrowing above its banking covenant limit, so the analysis effectively makes the decision for them.
Think of it
“Merger analysis is like evaluating whether two puzzle pieces fit together and create something more valuable combined.
Formula
Calculation
Combined earnings per share = (acquirer net income + target net income + net synergies) / total shares after the deal
Accretion or dilution = (combined earnings per share / acquirer standalone earnings per share) - 1
Acquirer plc earns net income of $96,000,000 with 60,000,000 shares in issue, so its standalone earnings per share is $96,000,000 / 60,000,000 = $1.60.
It acquires Target Ltd, which earns net income of $24,000,000, by issuing 15,000,000 new shares. Management expects net cost synergies of $6,000,000 a year once integration is complete.
Combined net income = $96,000,000 + $24,000,000 + $6,000,000 = $126,000,000. Total shares = 60,000,000 + 15,000,000 = 75,000,000. Combined earnings per share = $126,000,000 / 75,000,000 = $1.68.
Accretion = ($1.68 / $1.60) - 1 = 5%. The deal adds 8 cents per share, so it is 5% accretive in the first full year, and the analyst would then rerun the same numbers assuming only half the synergies land to see whether it still clears.Case study
Seen in the real world.
The following is a fictional, illustrative scenario. Brightpath Analytics, an invented software company, wanted to buy Kestrel Data Services and its finance director's first model showed the deal was 9% accretive, largely on the back of $11,000,000 in assumed annual synergies.
A second pass separated those synergies into their parts. Roughly $4,000,000 came from removing duplicated finance and human resources roles, which the team could name person by person, while the remaining $7,000,000 came from an assumption that Kestrel's customers would buy Brightpath's premium module at the same rate as existing clients did.
Rebuilding the analysis with cost synergies at full value and revenue synergies at 30% turned the headline number from 9% accretive to roughly break even. In this illustrative case Brightpath still bought Kestrel, but at a price $22,000,000 lower and with part of the consideration deferred against actual cross-sell performance.
Watch out
Common mistakes.
- Treating an accretive result as proof that a deal creates value, when accretion can be manufactured simply by paying with cheap debt.
- Counting synergies in full from day one rather than phasing them over two or three years and subtracting the cost of achieving them.
- Ignoring the target's off balance sheet commitments, such as long property leases or pension obligations, which change the real price being paid.
Questions
People also ask.
Is merger analysis only for listed companies?
No, private buyers run the same valuation and funding work; they simply focus on cash returns and debt capacity rather than earnings per share.
How far ahead should the model run?
Most analysts build three to five years of detail plus a terminal value, because integration benefits rarely show fully within the first twelve months.
What single number should a non-finance manager ask about?
Ask what the deal looks like if only half the synergies arrive, since that one question exposes most of the optimism in a model.
From the founder's library
Take it further with the book.
Build your financial confidence beyond this definition. Shihan's full-length guide, Accounting Fundamentals, takes the same plain-English approach and turns it into a complete, practical playbook for non-finance managers, business owners and students - with chapter-end quiz answers and presentation slides included.
25% off with code MMHQ25, applied at checkout. Priced in USD - checkout may show the equivalent in your local currency.
View the book and save 25%